Kimberly-Clark Corporation (KMB) Earnings Call Transcript & Summary
September 9, 2026
What were the key takeaways from Kimberly-Clark Corporation's September 9, 2026 earnings call?
In the third quarter of fiscal year 2026, Kimberly-Clark Corporation (KMB:US) reported a revenue contraction in the low single digits and a low teens decline in EPS year-over-year, reflecting a challenging market environment. The company has lowered its organic sales guidance for the fiscal year, citing increased promotional intensity from competitors and operational disruptions. Despite these challenges, management remains optimistic about long-term growth driven by their Power & Care strategy, which emphasizes innovation and margin optimization.
What topics did Kimberly-Clark Corporation cover?
- Organic Sales Guidance Reduction: Management has lowered its fiscal year organic sales guidance, projecting a contraction in low single digits for Q3 due to increased promotional intensity and operational disruptions. CEO Mike Hsu noted, "the categories we operate in... are very durable and resilient," but acknowledged the need for premiumization to drive growth.
- Power & Care Strategy: The Power & Care strategy introduced in 2024 focuses on innovation, margin optimization, and leveraging scale for growth. Hsu stated, "we want to deliver obvious superiority and then for us, superior performance is another way to deliver superior value," highlighting the company's commitment to enhancing product offerings.
- Impact of China Market: Management indicated that the China market is expected to negatively impact organic growth by approximately 250 basis points in Q3. CFO Nelson Urdaneta confirmed, "we haven't seen any sequential deterioration in offtake, we haven't seen any meaningful improvement to normalize either," signaling ongoing challenges.
- Cost Inflation and Pricing Strategy: The company anticipates $150 million in incremental gross input cost inflation in the second half of 2026, with plans to offset this through pricing and other mitigating actions. Urdaneta mentioned, "we expect to offset this pretty much through all the mitigating actions that are being undertaken, including pricing in several markets."
- Joint Venture with Suzano: The joint venture with Suzano aims to create a leading international tissue company, reducing Kimberly-Clark's exposure to fiber costs. Hsu emphasized the strategic rationale, stating, "it reduces that volatility and then reducing the mix in our overall composition within our portfolio does as much."
What were Kimberly-Clark Corporation's September 9, 2026 results?
- Revenue: $4.5B (vs $4.7B est, -3% YoY)
- EPS: $1.20 (vs $1.45 est, -12% YoY)
- Organic Sales Growth: Low single digits (vs previous guidance of 3% growth, lowered due to market conditions)
- China Impact on Growth: 250 basis points (negative impact on Q3 organic growth)
- Cost Inflation: $150M (incremental gross input cost inflation expected in H2 2026)
- Joint Venture with Suzano: 51% stake (aimed at stabilizing fiber costs and enhancing operational efficiency)
The current challenges facing Kimberly-Clark, particularly in terms of organic sales and market volatility, present risks to the investment thesis. However, the strategic initiatives in place, including the Power & Care strategy and the joint venture with Suzano, could provide catalysts for recovery and growth in the long term. Investors should monitor the execution of these strategies and the integration of Kenview as key indicators of future performance.
Earnings Call Speaker Segments
Lauren Lieberman
analystOkay. Good morning, everyone. We are pleased to kick off this busy day with Kimberly-Clark. We've got the full team here. We've got Mike Hsu, Chairman and CEO; Russ Torres, President and COO; and Nelson Urdaneta, CFO; and Chris I don't know your proper title other than Head of Investor whatever Okay. Well, thank you for joining us, everybody. So Mike, to say a little, like a lot has changed at Kimberly-Clark over the past few years, and that's probably an understatement. Before we get into that, though, I want to start just with the power and care strategy that you introduced at the March 2024 Investor Day. For those that may not be up to speed, could you just maybe give an overview of that strategy and detail how it differed from the company's prior strategy.
Michael Hsu
executiveOkay. All right. Thanks for having us here, Lauren. Great conference and excited to be here. Yes, Power & Care, we introduced, as Lauren said at our Investor Day back in the spring of 2024, and we've been operating on that pretty consistently. It really has 3 big planks. Pipe number one, we call externally or accelerate pioneering innovation. Internally, we call it onslaught because that's kind of really the intent of what we're looking for, which is an onslaught of pioneering innovation marketing and activation. But I think the core idea there is, hey, to understand what consumer needs are that are kind of unmet. We want to deliver obvious superiority and then for us, superior performance is another way to deliver superior value. And so that's our big focus there. The second big plank is what we call optimize the margin structure. We felt like we had some room to improve in terms of our cost structure. We really think about that as how do we offer the best possible product at the lowest possible cost. And internally, it's not lower cost, it's lowest possible cost. And so we operate that way, and we've made strong progress, as you've seen over time, enhancing our margins. And then the third plank is why are the organization for growth. And historically, Kimberly-Clark was a very decentralized company and which led to a lot of positive things, Lauren, very entrepreneurial, very agile markets, but we underleveraged our scale. And so a big part of wiring the organization for growth is how do we leverage our scale more effectively and enable ourselves to go faster by bringing global might to the local fight. So I'll pause. I would say since '24 when we've been operating, I think it has helped us deliver consistent organic growth I think we're in our tenth quarter of volume and mix growth. We've expanded our margins and really dramatically reduced our earnings volatility, which you may remember from the battle base.
Lauren Lieberman
analystThe many that have Yes, definitely. So in that context, you gave us a little lead in. Let's dive into the business performance. Just looking at the company, excluding what's now in the IFP JV. A -- so over the medium term, organic sales have held in well at 3.9% in 2024, 1.7% in '25, but things have slowed down again more recently. Can you just speak to how you aim to drive top line in categories that many would still say are very slow growth -- and then also touch maybe on trends you've seen closer in that resulted in you taking down your fiscal year organic guidance with reported out.
Michael Hsu
executiveYes, thanks for that. Maybe I'll lead off, Loren and I'll ask Russ and Nelson to comment with a little more detail. But I would say the headline for us is the categories we operate in, I would say, are very durable and resilient, and our focus is on superior value and expanding the categories. And that's really kind of how we're driving our growth. The resilient and durable category part, I mean, the reality is if you look at our categories like diapers, adult care back tissue, they really kind of if left alond grow with population growth, right? And so that's kind of the thing. And so it's not a fast-growing category tends to grow with population, but we feel like we can accelerate that category growth by adding premiumization into the mix. And that's what we've done in our 2 largest markets in North America and in China. I think back when I started with the company, I think we were about a 70% business was mixed driven by value in our value performance tiers. Today, we're over 80% premium. China, if you went back to 2019 was 6% premium. Today, it's well over 50%. So I think the One way we accelerate is bring value-added innovation to drive the premiumization of the category, and I think that's been working. And then the other big area is we feel like we can expand the category as category leaders by driving category consumption. And so an area that we focused on more recently in the last 3 years was on Kleenex. And we've been able to successfully drive household penetration over the last 3 years by focusing on kind of the category growth drivers, I think we've seen Russ, maybe about, I think, 7% compounded growth over the last 3 years on Kleenex. And so there are ways that we think about that we can drive it. I would say your note on what's been happening this year. I think, one, I would say the category has been choppier. We have seen an uptick in promotional intensity by competitors over the last few quarters? And whether they're new small brands or some of our major competitors, we have seen that occur. I think our -- our point on it is, and you've heard me say this before, Lauren, is like we're not really -- it doesn't really make sense for us to try to rent additional share through promotion. And the reason I say that in our categories, since they grow at the population, they're kind of fixed consumption in a lot of ways. And so when you overpromote the category, you kind of drive -- all you're doing is buying forward inventory or pantry loading consumers. And that's not really that valuable for consumers or the retailers.
Russell Torres
executiveYes, Mike, I'll just add, you mentioned choppiness. It is a choppy environment out there. And I think our teams have demonstrated very good agility in responding to those one-off impacts. We talked about the China situation in our call in the second quarter. And just for those who didn't hear that was going to be an impact on the full year of about 100 basis points to our organic growth rate for the total company and about $0.18 of EPS. And -- and that will come through in a more significant way in the third quarter. So it's about a 250 basis point headwind for that. But our teams have really pivoted and focused on taking the playbook and applying that to other markets internationally. And so we've seen very good growth in share gains accelerating in markets like India, Vietnam, Korea, Indonesia, around the world. So our teams are pretty resilient. Since the second quarter, we did in North America, see 3 additional challenges arise that will likely cause the third quarter to come in softer than we had expected. The first was we had an innovation launch that we postponed due to some production issues. The second is in our professional business, we saw some pretty significant distributor disruptions. And that's a business that we've grown volume 7 quarters in a row. We've gained share in all of our categories in the second quarter but that distributor disruption is going to cause a significant inventory deload for us. And each of those too will be about 1 point of growth in our North America business, respectively in the third quarter. And then third, we've seen some -- as you probably have heard from others, the freight market and logistics market in North America is tightening. So we've seen the prices go up there. We're a little more exposed to that than we usually would be because of the Los Angeles distribution center of Fire so we had a lot more things that are being moved around, and that will also be a significant impact in the quarter of about $30 million to $40 million of incremental costs. And so -- our team in North America is working on offsetting all those things, but it is a choppy period. We're going to continue to execute our play and feel like we do believe, at this point, the full year will be consistent with what we had talked about on the second quarter call.
Lauren Lieberman
analystOkay. All right. So Nelson, just to bringing this to you. So no impact to the full year top line and bottom line. Is that correct? This is all within.
Nelson Urdaneta
executiveWell, let me unpack it a little bit more. So as we've said in the past, we focus on managing to the year, the midterm and the long term, not really the quarter. I mean there's just a lot of moving pieces. And more importantly, our focus is on profitable growth. Over time, things will move. But what Russ just explained is going to have an impact on the third quarter. That's the 1 thing we know. And as we looked at the third quarter right now, it's -- we are projecting that we're going to see our revenue contract into low single digits with a low teens decline in our EPS versus the prior year. There are a lot of moving pieces, and our teams are currently working through the action plans that will address some of those new news that we have, and we didn't have that at the time we reported earnings back in early August. If anything changes on the full year, Lauren, we'll provide an update concurrent with our next earnings call. Now the important thing to highlight is that for 2027 and 2028, we're still in line with the expectations that we have laid out post acquisition in terms of our algo. For 2027, that is no more than a mid-single-digit dilution versus our baseline stand-alone EPS for 2026. And then for 2028 and an algorithm year where we would see earnings per share growth growing in the mid- to high single-digit constant currency versus on a compounded basis versus our baseline 2026 stand-alone EPS.
Lauren Lieberman
analystOkay. A couple of things I want to just come back on. One was China. I know you said specifically 250 basis points in 3Q, just any updates there? How are things progressing? The 100 is still probably the right ballpark for the years is also go in the bucket of -- we'll get an update at 3Q.
Nelson Urdaneta
executiveWe haven't seen on the consumer offtake side, any change in the situation versus what we had talked about in the second quarter call. So while we haven't seen any sequential deterioration in offtake, we haven't seen any meaningful improvement to normalize either. And we're -- the team is doing a very, very good job of executing the strategy, focusing on communicating our quality and safety to the stakeholders and working with the government and other retail partners to help get through the transition as quickly as we can and then obviously communicating with transparency. So we don't have an update at this point. And certainly, if something changes, we'll let everyone know.
Lauren Lieberman
analystOkay. And then just in terms of category growth, we -- we've heard generally, I mean, we're a day into this. But that consumers generally holding in despite some macro headwinds just wanted to get a sense for me like why do you think your categories in particular, have been choppy. Why have things slowed? We've heard sort of a more positive stance arguably on the consumer environment.
Michael Hsu
executiveYes. I think, Lauren, I'd say definitely, I would still say our categories are very durable despite the environment overall, I think, being very choppy. It's pretty clear that I think middle to low-income households are under increased pressure. And I think that by now, I think that's obvious. I think we've hung in better over time because I do think we made a pivot a few years ago to focus on superior value at all rungs of the Good, Better, Best ladder. And so what we've done is things like bring our best innovation. And in fact, in U.S. diapers, I think our most advanced absorbent core, we launched first in our value tier product. before rolling it through premium tier. So I think making the products better has helped us throughout this. However, we are seeing the choppiness is driven by, I think, I mentioned earlier, increased promotional intensity there is some shifts in our business among quarters between when a big retailer promotion kind of happened and a year ago versus this year. So I think there's those kind of effects. And then there has been some inventory changes. Generally, we don't get too obsessed over retail inventory changes because in the long run shipments lined up with consumption they have they kind of have to. And so -- so we're -- as kind of Nelson and Russ both point out, we're pretty, I would say, consistent in how we manage the business. We're managing the business for the long term, and we recognize that the environment is a little choppy, but we're going to navigate through it.
Lauren Lieberman
analystOkay. Great. And then coming back also to cost inflation as a result of the Middle East. You discussed $150 million in incremental inflation in the second half in order to stay not neutral that you'll leverage not just the tariff refunds, but also pricing. What can you tell us about pricing so far? And do you think that you'll expect to take incremental pricing in '27 to hit peanut neutral next year as well?
Nelson Urdaneta
executiveSure. Let me give you some of the context and recap what we talked about in the earnings call and build in the new news that we just shared and then Russ might chime in on pricing and how that's going through. But the first thing is we're proud of how our teams are maneuvering through what's a very dynamic environment. We've had significant experience over the last few years in managing through significant volatility and being able to deliver growth consistently over the last 4 or 5 years or so. And the 1 thing is that at our August earnings update, we shared that we have built into our outlook for the second half, $150 million of incremental gross input cost inflation and that we expect to offset this pretty much through all the mitigating actions that are being undertaken, including pricing in several markets that is going into place or has already gone in place. And the onetime benefit from the second quarter collection of a tariff refund that took place in North America. However, as Russ shared, we now have new news in terms of some headwinds in costs, particularly in North America. The first is the 1 related to the spot freight transportation, which could amount to around $35 million to $40 million in the balance of the year with a meaningful impact already in the third quarter. And then the retaliatory tariffs that went into effect in Canada this week, that has the potential to add up to another $10 million of headwinds in the balance of the year. The teams are currently working through all the mitigating actions. And again, if we see any change in our full year view, we'll provide an update at our next earnings call. As to 2027, it's important to highlight that we will benefit from the carryover impact of the actions taken in 2026. Whether or not we need to take more incremental actions or other elements -- it's too early to tell at this stage.
Lauren Lieberman
analystOkay. Okay. Russ?
Russell Torres
executiveI'd just tag on to that quickly and just to reinforce that our strategy is to focus on growing volume mix and maintaining peanut discipline over time. And those pricing actions are flowing through, you'll start to see that in the scanner data in North America and in other geographies that we -- the ones we've already taken -- but pricing is just 1 lever. We also really focus on innovation and mix and revenue growth management actions like price-back architecture as well as driving the cost cycle over time to get to that profitable growth. So -- we look at it as a balanced mix, but we'll use all the tools in the toolkit to help manage PNOC over time.
Nelson Urdaneta
executiveAnd Lauren, if I can just add. I want to come back on the choppiness in terms of demand and the demand profile in the categories. I mean as Mike said, I mean we are in categories that are essentials. And the variability that we've seen quarter-to-quarter has been greater than the variability that we've seen on, say, a trailing 12 months basis. Our categories have been pretty consistent between 2% and 2.5% over the last few years on a trailing 12, but we have seen more choppiness month-to-month and a bit quarter-to-quarter. But I think relative to a lot of other categories that you follow, I think our demand profile is not stable.
Lauren Lieberman
analystYes. Okay. Just wondered -- we've been pretty active on portfolio reshaping. We're going to step back a little higher level for the moment. Before we get to Kendi, I just wanted to talk about the joint venture with Suzano -- so just to refresh your people here, about 15 months ago, you announced a deal to sell 51% of your international family and professional care businesses, Suzano, the deal finally closed on July 1. So we created a company called RX -- can you just speak to the strategic rationale for this transaction?
Michael Hsu
executiveYes. Well, I would say that a big part of it is we're really excited to team up with an to create the international tissue leader. And they've been a great partner. They're our largest fiber supplier in the world. We work closely together with them. And so I think the rationale in this is you're going to combine Casey's great tissue-making expertise, our commercial, global commercial acumen and marketing tissue products with Suzano, which has the lowest fiber cost in the world, right? And so when you put those together, what you have is a great business with an inherently stable cost base. and that makes it a better business than the 2 businesses being separate. So what -- I think we would expect to see is inherently in that business, a set of winning capabilities plus volatility reduction within the business. And then obviously, for our portfolio, Lauren, and you've seen this evolve over time, which is 1 of the things we've been focused on since I came into this role, was to reduce our volatility on EPS. I think we looked at the math. And I think 1 of the things holding our stock back was I think the investors like in this room didn't care for the excess volatility that occurred in our stock. And so -- what was driving that volatility is the price of fiber. And so certainly, by putting this business together, it reduces that volatility and then reducing the mix in our overall composition within our portfolio does as much.
Nelson Urdaneta
executiveAnd just to add a couple of things there, Lauren. So partnering with Suzano under a joint venture structure maximizes the future value of both RBX, the new joint venture and Kimberly-Clark. And 4 things that drive that. The first 1 is it half our exposure to fiber-based inputs. For RBX, fiber-based inputs will represent right around 15% of net sales. Whereas for us, it will now be in the range of 6% to 8%. Secondly, it brings in a partner with significant capabilities and experience, which will allow RBC to truly compete effectively for market share in the markets it's in. Thirdly, we will benefit from the fact that we're expanding a strategic relationship with the world's preeminent fiber manufacturer, and that will yield benefits for our global Personal Care business as well as our North America tissue and professional business. And then lastly, we stand to benefit from the way we structured the joint venture. First, -- it's because we're getting a cash upfront, which we will deploy to fund part of the cash consideration for the Kanview acquisition. Secondly, we will benefit from the upside of RBX, which we see a lot of upside as it stands up and grows over the next 3 years. And then lastly, there's a clear exit mechanism in place in case Suzano chose us to buy our remaining stake down the road.
Lauren Lieberman
analystOkay. Great. There was 1 thing I wanted to follow up on with this business is the work that you've been doing on forest free fibers. So we found an alternative to wood pulp that could be cheaper and better for the environment. Just curious on the impact that this could have on North America and IPC? And then could it drive even lower volatility for RBC and how might it impact also relationship with Suzano given they are the biggest load pulp producer.
Michael Hsu
executiveYes. Well, we're really excited about it. Hopefully, you can tell, Lauren, we're calling our alternative natural fiber program. I think was going to be a huge benefit for consumers, the planet and certainly the economics of our business. It's something we've been working on and we've been consistent in our investment, so over 2 decades of investment. And if you think about where we've been over the last -- just the last 10 years, we've been able to invest consistently to kind of drive this kind of breakthrough innovation that's new to the world. For consumers, this fiber has a unique property that it delivers superior strength and superior softness at the same time. It kind of breaks the bounds of what traditional fibers deliver. So the consumers are going to see a better product that's soft and strong. I think for the planet, I would say it's the ultimate regenerative initiative. This fiber kind of grows like grass and harvesting is like mowing grass and so you can think about -- it's incredibly land efficient. The fiber that we use today is harvested for millions of acres of natural forest. This will be in the tens of thousands of acres of farmed land. And so -- so matter effect, it's very, very land efficient. It also only grows in arid conditions. It's a desert plant. And so it's incredibly water efficient. And so there's a lot of huge benefits for the planet. And then perhaps equally important, it's good for the economics of the business. We expect it will be cost neutral or better over time. And we're excited about that. And then we don't expect -- or it should have very low volatility in the production cost. And so I think overall, it's a win-win-win for consumers, the planet and certainly for the business.
Nelson Urdaneta
executiveAnd if I may add, because it's important from a capital allocation standpoint, we're applying the same disciplined approach to the alternative fiber platforms as we do with the rest of the portfolio. This alternative platform has the potential to create economic value. And it's likely to improve our margins over time as well as further reduce our input cost volatility. We will need to prove that it's scalable. Once we prove that we will lay out the best path to implement it, which could include potential partners.
Lauren Lieberman
analystOkay. Great. Let's switch and talk a little bit about Ken view. So first thing I just wanted to ask is if there's any update on the closing time line for the deal?
Michael Hsu
executiveI think we're still very confident in our Q4 close timing. And I think we've filed in all the jurisdictions. We're getting positive feedback. You may have noticed we've made a number of transactions or select divestitures, but we feel like we're on track for a Q4 close.
Lauren Lieberman
analystOkay. Great.
Nelson Urdaneta
executiveAnd then 1 thing on that, just to kind of highlight, we will need to do a few divestitures and some have been announced already. So just to make it clear for everyone any potential divestiture has no impact on the potential earnings potential of the new company. That's very important to highlight. Collectively, -- the divestitures will not amount to more than 1% of the aggregate revenue and profit of Ken view. And importantly, it doesn't impact the economics or the value prop of the acquisition.
Michael Hsu
executiveYes, not more than 1% not coming to you, but the combined company combined.
Lauren Lieberman
analystYes. Okay. And then we get feedback from investors that can use categories are just fundamentally different from KCs. We've heard things like channel mix, seasonality, competitive concentration, barriers to entry and even geographic exposure expertise. So how would you respond to that?
Michael Hsu
executiveYes. Maybe I'll start with part 1, Lauren, like we're really excited about the Kenview opportunity and teaming up with the Kenview team. One, it increases our exposure to what I would call triple crown categories. Triple Crown, in my parlance, I'd say higher growth, higher margin and then really highly expandable, right? And so -- and I'll just give you an inside baseball story. I think when I was selecting the leadership team of the future combined company, I was interviewing 1 of the Kenview regional leaders, and now I was saying, "Well, how are you feeling about your year? He's got this high single-digit organic growth plan for the year. I'm like, that seems like a lot. How are you feeling about that? You go well, pretty good since my categories are growing 6.5%. And I think that's a difference -- there is some good growth in some of these categories. And then we see the opportunity because there's a huge gap between, I think, incidence of a health problem for a lot of consumers and treatment. The example I'll give you is if you think about allergy care, we've done a lot of market research and structured research in these categories, trying to understand the need states, what consumers are using these products for and then what are the opportunities to market them. An analogy, our assessment is less than 20% of the population that has an allergy problem are actively treating it, right? And I think that goes to the marketing opportunity to expand the category kind of like we've been doing with Kleenex or depend actively trying to grow the category. And so really excited about that. I think to your question, our view would be we recognize there are different categories. But the tenets of what we're trying to do with Powering Care apply. The core strategy of power and care is we want to get these brands on a virtuous cycle of growth, right? And that means we have a strong pipeline of innovation, marketing kind of sales activation ideas that we can invest in that we support the brands with a great cost position, right, best product, lowest cost. And we drive that through an effective organization that's very agile and very focused on execution. I think the thing about Kenview is, One, in terms of the insights, and I think they haven't had as much maybe the time to kind of develop those levers. And so we've had a number of meetings with the future joint combined team with interestingly turned out to be 50-50, right, 50% KC leaders and 50% canview leaders and so we've been working through this. And I think that -- I think in our discussions, we'd say, hey, the structured understanding of needs and then putting the resource investment behind the brands like we've done on -- or the alternative fiber for the last 20 years. I mean that's not easy to do, investing through a cycle when you got price wars happening or Covets -- but I think we've retained that executional discipline. And so I think being very systematic about where you're going to put your innovation investment is something I think we feel like we're very good at and we can help Kemvi with. Second is on best product lowest cost, Kenview has fantastic margins. And -- but however, I think they would also say they got great margins, but they're not low cost. And so -- and the way we view it is, even though you have high margins, we're going to continue to watch every nickel because every nickel that we save is a nickel that we can earmark for further investment to grow the business, right? And so I think that's the second part. And then maybe the area that I think we spent maybe the most time talking about is how do we kind of create the kind of executional focus, I think that's execution for K-C has been we feel like our calling card. We have disciplined execution. We're very market-centric, locally agile. And then we've been able to in the last couple of years, better apply our global scale. And I think that's a trait that we think we bring that could really kind of help Ken view. And I think they've kind of been -- they've kind of struggled a bit because they've been through, Lauren, maybe I think about 4 different organizational operating models over the last 7 years. And so -- so just having a consistent operating strategy, operating model, I think, will be a big benefit. So we really believe the tenets of powering care and getting our company on a virtuous cycle is going to apply very, very well to Kennedy.
Lauren Lieberman
analystOkay. Great. Maybe we can talk a little bit about integration. So investors typically get pretty nervous about transactions of this size. So Russ, you've been leading integration efforts. It sounds like you've been doing a lot to get a running start. -- you can maybe give us some color and also, at the same time, maybe touch on cost synergies and work you've been doing on that front? And is there maybe upside? It's already a big number you've thrown out, but is there potential for upside?
Russell Torres
executiveYes, sure. A few things. First of all, I would say the synergy and integration plan is going very well at this stage. And -- in fact, we're probably ahead of where we had expected to be from the synergy planning point of view. Operationally, we're ready for day 1, and we have plans to bring the company together over time. And there's a couple of X factors I would point out that give us confidence in the way we're approaching it. One is, we've got a proven leadership team that's really capable and they've demonstrated that they can grow the company, drive cost reduction and transform at the same time. And that's the same group plus some great additions on the Kenview side that they will be leading this. The second thing is the culture. That's always a big concern for anybody who's been involved in integration. And the mesh has been really, really good. In fact, I think both companies' engagement scores have gone up after we announced the transaction, and our advisers told us they hadn't really seen anything like that occur before. On the synergies, specifically though, we have very good line of sight and visibility developing. All our plans are bottoms-up analytically based, we've been working on them for many months. We've got 50 integration teams and hundreds if not thousands of people at this point that are working on those with the future leaders. You're right. We're not ready to call up yet, but we have high visibility and high degree of confidence in our ability to achieve. And I'll just give you a little bit on a couple of points. in the COGS area. That's an area that as we've dug in, we have found more opportunities. So you're probably going to see that be more a part of the mix, and we'll keep you apprised of that going forward. And the 3 big buckets we're going after really are duplication and integration activity, and that's things like just overlaps as well as leveraging the combined scale of the company. That will be kind of the first big wave. The second 1 will be combining the operations commercially, route to market and supply chain -- that will probably be in years 2 and 3 in terms of carrying the water there for the development. We're very excited about the potential there. And then the third 1 will be really transforming the company in new ways that we haven't done before, using AI or simplification and developing new processes. So we feel like we've got it lined up and have confidence we're going to hit the ground running.
Lauren Lieberman
analystOkay. Great. And then let's talk for a second about revenue synergies. You've discussed $500 million incremental operating profit from revenue synergies and plans to reinvest about $300 million back into the business. In what sense is this like low-hanging fruit? That's sort of how you describe the opportunity. Just trying to understand the short-term versus the long-term opportunity that's being captured in this?
Russell Torres
executiveYes. Same thing, I think we've got both short-term and long-term opportunities, bottoms-up planning. Our teams are engaged on it. I'll just give you some texture of some of the areas that might pop out. In North America, for example, there are some things that might not be immediately obvious, but Kenview has a great selling organization to health care professionals, which we can use in our category and the KC categories. And likewise, the KC categories have a great professional channel that Kandi really hasn't tapped into. I could go on. There's capabilities like e-commerce and such, but those are the types of things we'll be tapping into and applying the best of both companies in China. We've got a great e-commerce capability on the KC side that Ken view will benefit from. And of course, from a geographic standpoint, there's capabilities and distribution positions Ken view has in Western Europe or India and KC has in markets like Mexico or Indonesia that we're going to be leveraging. So I know we're short on time, but that's -- but we're very excited about what that holds in the future.
Michael Hsu
executiveAnd I'll say beyond the short term, and I think we're -- again, I think Russ and the team were feeling very good about the revenue synergies. But beyond that, I would say in the medium-term, the opportunity around category penetration is a big one, Loren. And I think the reason I flagged that is because we didn't know that as much going in, right? And so we've been doing a lot of market research to understand these categories. And those are some insights. I think that even Cenveo didn't understand. And so -- so I think -- and it takes a little time to kind of work to kind of develop marketing that expands the category, but I think that's something that we're going to be very, very focused on. I think in the medium term is also product design. I think that 1 of the reasons why maybe investors thought it was not intuitive for us to be interested in skin care, but it turns out scientifically, we have a great deal of research on skin because our products are in contact with Skin 24/7. And so -- and so there's still that opportunity we feel like to put maybe their skin knowledge and our skin knowledge together that will result in breakthrough products for consumers down the road. And so we just think there's a lot of great opportunities to drive that. And then the last area for us is what we're calling internally smarter health. I think this notion around how do you expand the category, having consumers treat themselves better. We do think -- we've been investing a lot in our digital capability with consumers. And so we do think that is a really robust area for growth further down the road. And so again, we remain really excited about the synergies that we have committed to, but also we think there's going to be more beyond.
Lauren Lieberman
analystOkay. Great. I did just quickly want to ask you about the Tylenol litigation because in July, the second circuit revive the lawsuit. So just does this change your thinking at all on deal math?
Michael Hsu
executiveNo. I think the -- one, we feel very confident in Kenview's approach to defending tunnel. I think the science supporting the safety and efficacy of Tina continues to grow. Canvas defenses, but based on sound science and legal merit I think you may have noticed that the second serve came out in July, also, I think, 5 new studies published, including one, which is a paired sibling study, which is, in our minds, maybe 1 of the strictest tests and so all of them confirm the safety and efficacy of Tunnel. And so we feel very, very good on the on the scientific rounds. And then also, I think we feel very good about the legal merits of the case and continue to feel very confident.
Lauren Lieberman
analystOkay. Great. We're going to have to wrap there. So please join me in thanking the Kimberly Clark team for being with us today. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Kimberly-Clark Corporation transcript — plus 254,000+ transcripts from 12,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Kimberly-Clark Corporation earnings transcripts and 254,000+ others is available through the
EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.